Year |
Citation |
Score |
2008 |
Roberts L, Egan TJ, Joiner KA, Hoppe HC. Differential effects of quinoline antimalarials on endocytosis in Plasmodium falciparum. Antimicrobial Agents and Chemotherapy. 52: 1840-2. PMID 18316523 DOI: 10.1128/AAC.01478-07 |
0.355 |
|
2006 |
Massimine KM, McIntosh MT, Doan LT, Atreya CE, Gromer S, Sirawaraporn W, Elliott DA, Joiner KA, Schirmer RH, Anderson KS. Eosin B as a novel antimalarial agent for drug-resistant Plasmodium falciparum. Antimicrobial Agents and Chemotherapy. 50: 3132-41. PMID 16940112 DOI: 10.1128/Aac.00621-06 |
0.623 |
|
2005 |
Massimine KM, Doan LT, Atreya CA, Stedman TT, Anderson KS, Joiner KA, Coppens I. Toxoplasma gondii is capable of exogenous folate transport. A likely expansion of the BT1 family of transmembrane proteins. Molecular and Biochemical Parasitology. 144: 44-54. PMID 16159678 DOI: 10.1016/J.Molbiopara.2005.07.006 |
0.596 |
|
2003 |
Hinshaw JC, Suh DY, Garnier P, Buckner FS, Eastman RT, Matsuda SP, Joubert BM, Coppens I, Joiner KA, Merali S, Nash TE, Prestwich GD. Oxidosqualene cyclase inhibitors as antimicrobial agents. Journal of Medicinal Chemistry. 46: 4240-3. PMID 13678402 DOI: 10.1021/Jm034126T |
0.313 |
|
2003 |
Atreya CE, Johnson EF, Irwin JJ, Dow A, Massimine KM, Coppens I, Stempliuk V, Beverley S, Joiner KA, Shoichet BK, Anderson KS. A molecular docking strategy identifies Eosin B as a non-active site inhibitor of protozoal bifunctional thymidylate synthase-dihydrofolate reductase. The Journal of Biological Chemistry. 278: 14092-100. PMID 12556445 DOI: 10.1074/Jbc.M212690200 |
0.614 |
|
2002 |
Que X, Ngo H, Lawton J, Gray M, Liu Q, Engel J, Brinen L, Ghosh P, Joiner KA, Reed SL. The cathepsin B of Toxoplasma gondii, toxopain-1, is critical for parasite invasion and rhoptry protein processing. The Journal of Biological Chemistry. 277: 25791-7. PMID 12000756 DOI: 10.1074/Jbc.M202659200 |
0.422 |
|
1997 |
Silverman JA, Hayes ML, Luft BJ, Joiner KA. Characterization of anti-Toxoplasma activity of SDZ 215-918, a cyclosporin derivative lacking immunosuppressive and peptidyl-prolyl- isomerase-inhibiting activity: Possible role of a P glycoprotein in Toxoplasma physiology Antimicrobial Agents and Chemotherapy. 41: 1859-1866. PMID 9303374 |
0.386 |
|
1995 |
Beckers CJM, Roos DS, Donald RGK, Luft BJ, Schwab JC, Cao Y, Joiner KA. Inhibition of cytoplasmic and organellar protein synthesis in Toxoplasma gondii: Implications for the target of macrolide antibiotics Journal of Clinical Investigation. 95: 367-376. PMID 7814637 |
0.306 |
|
1995 |
Conrad Schwab J, Afifi Afifi M, Pizzorno G, Handschumacher RE, Joiner KA. Toxoplasma gondii tachyzoites possess an unusual plasma membrane adenosine transporter Molecular and Biochemical Parasitology. 70: 59-69. PMID 7637715 DOI: 10.1016/0166-6851(95)00005-L |
0.307 |
|
1990 |
Joiner KA, Fuhrman SA, Miettinen HM, Kasper LH, Mellman I. Toxoplasma gondii: Fusion competence of parasitophorous vacuoles in Fc receptor-transfected fibroblasts Science. 249: 641-646. PMID 2200126 DOI: 10.1126/Science.2200126 |
0.364 |
|
1989 |
Danner RL, Joiner KA, Rubin M, Patterson WH, Johnson N, Ayers KM, Parillo JE. Purification, toxicity, and antiendotoxin activity of polymyxin B nonapeptide Antimicrobial Agents and Chemotherapy. 33: 1428-1434. PMID 2554795 |
0.357 |
|
1988 |
Rimoldi MT, Sher A, Heiny S, Lituchy A, Hammer CH, Joiner K. Developmentally regulated expression by Trypanosoma cruzi of molecules that accelerate the decay of complement C3 convertases. Proceedings of the National Academy of Sciences of the United States of America. 85: 193-7. PMID 3277170 DOI: 10.1073/Pnas.85.1.193 |
0.404 |
|
1986 |
Joiner K, Sher A, Gaither T, Hammer C. Evasion of alternative complement pathway by Trypanosoma cruzi results from inefficient binding of factor B. Proceedings of the National Academy of Sciences of the United States of America. 83: 6593-6597. PMID 2944112 DOI: 10.1073/Pnas.83.17.6593 |
0.383 |
|
Show low-probability matches. |